ALK and non-small cell lung carcinoma: All clinical and demographic features were assessed at different time points during the follow-up: at diagnosis of advanced ALK+ NSCLC; during treatments prior to alectinib treatment; at initiation, during and after alectinib treatment; and after subsequent lines of treatment.